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Abstract
Background: Left ventricular (LV) hypertrophy is common among patients on hemodialysis. While a relationship 
between blood pressure (BP) and LV hypertrophy has been established, it is unclear which BP measurement method is 
the strongest correlate of LV hypertrophy. We sought to determine agreement between various blood pressure 
measurement methods, as well as identify which method was the strongest correlate of LV hypertrophy among 
patients on hemodialysis.
Methods: This was a post-hoc analysis of data from a randomized controlled trial. We evaluated the agreement 
between seven BP measurement methods: standardized measurement at baseline; single pre- and post-dialysis, as 
well as mean intra-dialytic measurement at baseline; and cumulative pre-, intra- and post-dialysis readings (an average 
of 12 monthly readings based on a single day per month). Agreement was assessed using Lin's concordance 
correlation coefficient (CCC) and the Bland Altman method. Association between BP measurement method and LV 
hypertrophy on baseline cardiac MRI was determined using receiver operating characteristic curves and area under the 
curve (AUC).
Results: Agreement between BP measurement methods in the 39 patients on hemodialysis varied considerably, from 
a CCC of 0.35 to 0.94, with overlapping 95% confidence intervals. Pre-dialysis measurements were the weakest 
predictors of LV hypertrophy while standardized, post- and inter-dialytic measurements had similar and strong (AUC 
0.79 to 0.80) predictive power for LV hypertrophy.
Conclusions: A single standardized BP has strong predictive power for LV hypertrophy and performs just as well as 
more resource intensive cumulative measurements, whereas pre-dialysis blood pressure measurements have the 
weakest predictive power for LV hypertrophy. Current guidelines, which recommend using pre-dialysis measurements, 
should be revisited to confirm these results.
Background
Hypertension is common among patients on hemodialy-
sis (HD) and is associated with an increased risk of coro-
nary artery disease, congestive heart failure,
cerebrovascular complications, mortality and left-ven-
tricular (LV) hypertrophy[1-3]. Cardiovascular disease
accounts for the majority of deaths in patients with end
stage renal disease (ESRD)[4,5], thus adequate blood
pressure (BP) control is important to reduce the risk of
adverse cardiac events. LV hypertrophy, in itself, affects
up to 80% of ESRD patients[2], is an established cardiac
manifestation of chronic hypertension[6] and an inde-
pendent predictor of cardiovascular events and mortality
in both the general and ESRD population[7,8]. Although
the relationship between hypertension and cardiovascu-
lar morbidity and mortality is not consistently reported in
the HD patient population[9], it is generally accepted that
BP control is important for cardiovascular risk reduction
in these patients[10]. Recommendations for BP measure-
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ment among patients on dialysis, including timing (pre-
vs. post-dialysis), target levels, and methods of measure-
ment, are variable, while in general, blood pressure con-
trol in HD patients remains poor[1,11].
Although the most accurate BP measurement tech-
nique among patients on HD is unknown, it has been
demonstrated that casual dialysis-unit BP measurements
differ considerably when compared to ambulatory and
standardized BP measurements[12-14], and correlate
poorly with target organ damage[13]. Further, it was
shown that BP measurements obtained outside the dialy-
sis unit (home and ambulatory BP measurements) were
more strongly correlated with LV hypertrophy than those
obtained within the dialysis unit[12,13]. Previous studies
have produced inconsistent results with respect to the BP
measurement method which best predicts LV hypertro-
phy[15,16].
By using more sensitive measures of LV mass, and more
frequen t measuremen ts of BP , we sought t o determine
the agreement between various BP measurement meth-
ods, at different times (pre-, intra- and post- dialysis)
among patients on HD. We also sought to determine the
association between BP measurement methods and LV
hypertrophy. Further, we hypothesized that BP values
obtained by a standardized BP protocol (as recom-
mended by national guidelines) would be more closely
associated with LV hypertrophy than BP values obtained
by other techniques.
Methods
Subjects
This study involves a post-hoc analysis of data collected
within a previously reported randomized controlled trial,
where details of the subjects and protocol are previously
described[17]. Subjects included in this analysis were lim-
ited to those from the University of Calgary who under-
went cardiac magnetic resonance imaging (cMR) as a
baseline procedure during the clinical trial, but prior to
the intervention. Subjects from the University of Alberta
were excluded because of the absence of serial dialysis-
associated BP measurements.
Eligible subjects were 18 years of age or older, receiving
in-center, self-care or home hemodialysis three times a
week. The study protocol was approved by the University
of Calgary bioethics committee.
Standardized BP at baseline
Standardized BP measurements were obtained at base-
line by a physician using a mercury sphygmomanometer
in accordance with the Canadian Hypertension Educa-
tion Programs protocol for blood pressure measure-
ment[18]. Three sitting BP measurements were taken 5
minutes apart, after the patient had been resting in a
quiet room for at least 5 minutes. The average of the last
two measurements was utilized as the standardized BP
value for this study[17]. The standardized BP measure-
ments were obtained prior to dialysis but within two
weeks of the cMR exam.
Casual BP measurements at a single hemodialysis session 
at baseline
A  s i n g l e  p r e -  a n d  p o s t  d i a l y s i s  B P  m e a s u r e m e n t  w a s
taken by a dialysis unit nurse with patients in a sitting
position, within 30 minutes prior to and following the
dialysis session using either the automated GAMBRO
Phoenix or manually using a mercury sphygmometer on
the non-fistula arm. Intra-dialytic BPs were recorded
every 15-30 minutes during dialysis. The average value of
all of the BP measures taken during a single dialysis ses-
sion, which ranged from 2 to 11 readings per dialysis ses-
sion (median 7), was used to determine the intra-dialysis
BP.
Cumulative BP measurements
Monthly pre-, intra- and post-dialysis BP measurements
were retrospectively collected from hemodialysis records
for a single hemodialysis session each month during the
12 month period prior to the cMR examination. These
casual BP measurements were obtained by dialysis staff
or by the patient (for those patients on home conven-
tional hemodialysis).
Left ventricular mass and left ventricular hypertrophy
cMR was performed on 1.5-T MRI systems (Avanto® or
Sonata®; Siemens Medical Solutions, Erlangen, Germany)
with 8-channel cardiac coils. Standard, breath-held, ret-
rospectively electrocardiogram-gated gradient-echo
sequences (steady state free precession, SSFP) in contigu-
ous short-axis views (25 phases, slice thickness 8 mm)
were applied. The evaluation of the cMR images was per-
formed in a professional core lab (CIRCLE International
Ltd., Calgary, Canada) by readers blinded to BP measure-
ment data. Papillary muscles were included in the LV
myocardial mass calculation. The formula by DuBois and
DuBois[19] was used to index L V mass to body surface
area. The presence of LV hypertrophy was defined as LV
mass/m2  >83 for males and LV mass/m2  >67 for
females[20].
Laboratory measurements
Lab records for the 12 months prior to the cMR proce-
dure were extracted from the Southern Alberta Renal
Program database. Given the small sample size, we chose,
a priori, to limit our assessment to serum calcium, phos-
phate, hemoglobin and parathyroid hormone (PTH) as
these have been linked to alterations in LV structure[21].
Serum calcium was not corrected for serum albumin val-
ues. PTH was measured using the Nichols bio-intactKhang ura  et al. BMC Nephrology 2010, 11:13
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assay. Mean values were collected at baseline and in the
12 months prior to the cMR.
Statistical analysis
Subject characteristics are presented as mean ± standard
deviation (SD) or median and inter-quartile range (IQR)
for continuous variables as appropriate, and number
(percent) for categorical data. All BP measurements are
reported as mean ± SD. Agreement between BP measure-
ment methods was assessed using two statistical meth-
ods. Lin's[22,23] concordance correlation coefficient
(CCC) was used to measure overall agreement between
any two measurement methods. Lin's CCC incorporates
both bias and precision, with a CCC value of 1 indicating
perfect agreement and -1 indicating perfect inverse
agreement. CCC values are reported with their respective
95% confidence intervals (CI). The second statistical
method used to assess agreement was the Bland and Alt-
man method[24], which plots the difference between
pairs of measurements on the y-axis against the mean of
each pair on the x-axis. The 95% CI are also presented.
Pearson's product moment correlation coefficients are
reported for each method against LV mass, standardized
to body surface area.
Multivariate linear regression analyses, with LV mass
corrected for body surface area as the dependent variable
and BP parameters as independent variables, were used
to determine the potential confounding effects of hemo-
globin, calcium-phosphate product, PTH, age and dialy-
sis vintage. Receiver operated characteristic (ROC)
curves, and area under the curve (AUC) statistics, with
their respective 95% CI, were generated to compare the
test performances of various BP methods in detecting the
presence of LV hypertrophy. Only the results for systolic
blood pressure (SBP) are shown as the results of the dia-
stolic blood pressure analysis did not appreciably change
the outcomes of this study. All analyses were performed
using Stata 9.2 (Stata Corporation, College Station,
Texas).
Results
Patient and baseline characteristics
A total of 39 patients were included in the study . The
mean age of study subjects was 54 years and two-thirds
were male (Table 1). The majority of subjects were taking
antihypertensive medications, the most common being
angiotensin converting enzyme (ACE) inhibitors or
angiotensin receptor blockers. LV hypertrophy, as mea-
sured by cMR, existed in 29 (74.4%) study subjects. Blood
pressure results obtained by the various methods are
detailed in Figure 1. Pre-dialysis BP values were higher
than post-dialysis BP values, and both baseline and
cumulative pre-dialysis BPs were higher than the stan-
dardized BP taken pre dialysis.
Agreement between BP measurement methods
The agreement levels for the different methods for SBP
measurements are shown in Table 2. Agreement between
methods was highly variable, from a CCC of 0.35 (95% CI
0.05, 0.59) for baseline pre-dialysis and standardized
methods to a CCC of 0.94 (95% CI 0.89, 0.97) for cumula-
tive intra-dialysis and cumulative post-dialysis methods.
The 95% CI for the CCC's for all methods overlapped,
suggesting no significant difference in agreement
between BP measurement methods. The Bland-Altman
analysis confirmed this, showing no consistent bias
between the different methods.
Although not statistically significant, standardized,
post- and intra-dialysis measurements (baseline and
cumulative) had moderate to high agreement (CCCs 0.67
to 0.94), while the comparison of each method with base-
line pre-dialysis BPs showed lower levels of agreement
(CCCs 0.35 to 0.62).
Association between BP measurement method and LV 
mass
Correlations between BP measurement methods and LV
mass are shown in Table 3. Standardized BP had a corre-
lation of r = 0.44 (P = 0.005). Baseline post- and intra-
dialysis methods had correlations of 0.60 (P = 0.0001) and
0.59 (P < 0.0001) respectively, slightly higher than the cor-
relation for cumulative post- and intra- dialysis methods.
The correlation between BP method and LV mass was
significant (P < 0.05) for all methods except baseline pre-
dialysis (r = 0.30, P = 0.068). Results were unchanged
when adjusted for hemoglobin, calcium-phosphate prod-
uct, PTH, age and dialysis vintage.
ROC curves for the SBP measurements and LV hyper-
trophy are shown in Figure 2 and their respective AUC
Figure 1 Summary of systolic blood pressure measurements by 
different methods (n = 39) .Khangura et al. BMC Nephrology 2010, 11:13
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values are provided in Table 3. All the SBP values were
related to LV hypertrophy. All of the BP measurement
methods had similar AUC values and their 95% CIs over-
lapped; hence they were not significantly different from
each other. AUC values were highest for standardized
systolic (AUC 0.79), baseline post- (AUC 0.79) and base-
line intra-dialysis (AUC 0.80). Both cumulative intra- and
post-dialysis methods had an AUC of 0.74 while the AUC
for the baseline pre-dialysis method was 0.71.
Discussion
In this study we investigated the agreement between
standardized and casual (single dialysis session and 12
month cumulative) BP measurement methods, and their
association with left ventricular mass in hemodialysis
patients. Current guidelines [25,26] recommend the use
of a single pre-dialysis BP measurement for the care and
management of chronic hemodialysis patients. However
our analysis of pre-, intra-, post- and standardized BP
measurements suggests that a single pre-dialysis mea-
surement is the least accurate method of BP assessment
and demonstrates the weakest performance at predicting
LV hypertrophy compared to cumulative and standard-
ized measurements.
Intra- or post- dialysis BP measurements collected over
several months may provide a more accurate assessment
of BP in a stable, chronic HD patient rather than a single
pre-dialysis measurement. However, this is resource
intensive and often impractical in the clinical setting. Fur-
thermore, in spite of extremely high agreement (CCC of
0.94), cumulative intra- and post-dialysis BP measure-
ments were not the strongest predictors of LV hypertro-
phy, which is the more clinically significant outcome. BP
values obtained by the standardized BP measurement
protocol were closely associated with L V mass, but no
more so than a single intra-dialysis or single post-dialysis
measurement, all three of which had similar and strong
predictive power for determining LV hypertrophy.
While the relationship between BP and mortality in
ESRD patients is not clear[9,27,28], it is well accepted
that high BP contributes to LV hypertrophy - which itself
is an independent risk factor for morbidity and mortality
in the ESRD population[7,8]. The prevalence of LV
hypertrophy in our study, 74.4%, is similar to that
reported in prior studies[13,29].
Two previous studies of BP as a predictor of LV geome-
try both found pre-dialysis BP's to be strong determi-
nants of LV hypertrophy[15,16]. These studies however
were small, used a less sensitive measure of LV mass
(echocardiography), and only measured BP over 12 dialy-
sis sessions. A more recent study of 140 hemodialysis
Table 1: Baseline characteristics of study subjects
Characteristic † N = 39 
Age, years 54.4 ± 13.3
Male gender, n (%) 26 (66.6)
Caucasian, n (%) 33 (84.6)
Body mass index (kg/m2) 25.3 ± 5.4
Time on dialysis, years 5.0 ± 4.6
Prior renal transplantation, n (%) 12 (30.8)
Cause of ESRD, n (%)
Diabetic nephropathy 12 (30.0)
Hypertension/vascular 3 (7.7)
Glomerulonephritis 10 (25.6)
Polycystic kidney disease 4 (10.3)
Urologic 4 (10.3)
Other 6 (15.4)
Comorbid illnesses, n (%)
Ischemic heart disease 17 (43.6)
Congestive heart failure 10 (25.6)
Peripheral vascular disease 6 (15.4)
Cerebrovascular disease 6 (15.4)
Diabetes mellitus 16 (41.0)
Medication use, n (%)
ASA 17 (54)
ACE inhibitor or ATII antagonist 25 (64)
Calcium channel blocker 21 (54)
Beta-blocker 16 (41)
Other anti-hypertensive 5 (13)
Any anti-hypertensive 33 (85)
Hemoglobin, g/dL 121 ± 13.7
Serum calcium, mmol/L 2.32 ± 0.24
Serum phosphate, mmol/L 1.69 ± 0.43
Calcium-phosphate product, mmol2/:L2 3.94 ± 1.10
Parathyroid hormone, pg/ml 239 (83, 391)
Left ventricular mass 173.7 ± 61.0
Left ventricular mass/m2 93.5 ± 31.6
Left ventricular hypertrophy, n (%) 29 (74.4%)
†Reported as mean ± SD or median (IQR) where data is skewed for 
continuous variables and number (%) for categorical data.Khangura et al. BMC Nephrology 2010, 11:13
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patients reported that out-of-clinic recordings (1-week-
averaged home BP readings) performed better at predict-
ing LV hypertrophy than routine and standardized BP
recordings obtained pre- and post-dialysis in the dialysis
unit[13]. Unfortunately, access to home BP monitors or
supervised ambulatory BP monitoring is not always avail-
able and convincing patients to measure BP at home
when it is measured so frequently in HD units, may be
difficult.
BP management in HD patients is partly dependent on
the ability of physicians to accurately assess BP levels,
which remains a challenge. In the absence of a universally
accepted method for BP assessment among patients on
h e m od i a l y s i s,  w e  s e l e c t ed  s t a n d a r d iz e d  B P  a s  t h e  g o l d
standard for the purpose of this study, as it was based on
a protocol established and endorsed by national hyper-
tension guidelines[18]. Previous studies provide conflict-
ing results as to whether pre-dialysis, post-dialysis, inter-
dialytic or a combination of BP measurements methods
are most valuable for clinical decision making[15,30,31].
However the issue of accuracy of BP measurement in the
dialysis unit is often ignored. Our results are consistent
with previous reports [11-14,32] suggesting that routine
dialysis BP measurements are in fact highly inaccurate.
Our results should be interpreted in the context of the
study limitations. Firstly, our sample size was small,
including 39 patients. Despite the small sample size, our
use of cMR enabled us to use a more accurate measure of
LV mass; thus our point estimates are more precise than
those of previous studies[13]. Secondly, as a single-centre
Table 2: Agreement levels between different methods for all systolic blood pressure measurements.
Baseline measurements Cumulative measurements
Standard Pre-dialysis Post-dialysis Intra-dialysis Pre-dialysis Post-dialysis Intra-dialysis
Standardized
-5.8 (-13.9, 2.2)
Baseline Pre- dialysis (-54.5, 42.9) --- --- --- --- --- ---
0.35 (0.05, 0.59)
1.0 (-5.3, 7.3) 6.8 (0.4, 13.2)
Post -dialysis (-37.0, 39.0) (-31.9, 45.5) --- --- --- --- ---
0.58 (0.33, 0.75) 0.52 (0.27, 0.71)
-1.1 (-7.0, 4.7) 4.6 (-1.8, 11.0) -2.2 (-5.5, 1.0)
Intra-dialysis (-37.6, 35.1) (-34.0, 43.2) (-21.8, 17.3) --- --- --- ---
0.62 (0.39, 0.78) 0.55 (0.29, 0.73) 0.87 (0.77, 0.93)
-8.6 (-14.3, -2.8) -2.7 (-8.4, 2.9) -9.6 (-15.0, -4.1) -7.3 (-12.1, -2.5)
Cumulative Pre- dialysis (-43.2, 26.1) (-36.7, 31.2) (-42.5, 23.3) (-36.4, 21.8) --- --- ---
0.57 (0.34, 0.73) 0.62 (0.39, 0.78) 0.54 (0.31, 0.71) 0.65 (0.45, 0.79)
0.6 (-4.5, 5.8) 6.5 (0.2, 12.8) -0.36 (-5.1, 4.4) 1.9 (-2.6, 6,3) 9.2 (5.5, 12.9)
Post-dialysis (-30.4, 31.7) (-31.60 44.5) (-29.1, 28.4) (-25.1, 28.8) (-13.2, 31.6) --- ---
0.67 (0.47, 0.80) 0.46 (0.20, 0.66) 0.67 (0.47, 0.81) 0.72 (0.54, 0.84) 0.67 (0.49, 0.80)
0.2 (-5.0, 5.4) 6.0 (0.0, 12.0) -0.8 (-5.4, 3.8) 1.4 (-2.4, 5.3) 8.8 (5.8, 11.7) -0.4 (-2.3, 1.3)
Intra-dialysis (-31.2, 31.6) (-30.4, 42.4) (-28.5, 27.0) (-21.9, 24.8) (-9.1, 26.6) (-11.4, 10.5) ---
0.65 (0.46, 0.79) 0.49 (0.25, 0.68) 0.69 (0.50, 0.82) 0.78 (0.64, 0.87) 0.75 (0.61, 0.85) 0.94 (0.89, 0.97)
Each cell contains the mean difference (95% confidence interval) (first row), 95% agreement limits (second row) and CCC (95% confidence interval) 
(third row).
† Mean difference was calculated by subtracting the row from the column.Khangura et al. BMC Nephrology 2010, 11:13
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observational study, the generalizability of our results
could be questioned. However the lenient inclusion and
exclusion criteria does increase generalizability of the
results. The cross-sectional nature of the data for baseline
B P  m e a s u r e m e n t ,  l a c k  o f  a m b u l a t o r y  b l o o d  p r e s s u r e
measurements and assessment of LV hypertrophy with-
o u t  a n  a s s e s s m e n t  o f  v o l u m e  s t a t u s  p r e v e n t s  u s  f r o m
drawing firm conclusions, however, the results are fur-
ther supported by cumulative BP measurements obtained
over a 12 month period. Finally, our study included
Table 3: Pearson's product correlation coefficients for baseline and cumulative systolic BP measurement methods with 
LVM/m2 † and ROC statistics for LV hypertrophy††
BP Measurement Method  Correlation with LVM/m 2 ROC AUC (95% Confidence Interval) 
Pearson's r P value 
Standardized 0.44 0.005 0.79 (0.64, 0.94)
Pre-dialysis 0.30 0.068 0.71 (0.53, 0.89
Baseline Post-dialysis 0.60 0.0001 0.79 (0.64, 0.93)
Intra-dialysis 0.59 <0.0001 0.80 (0.64, 0.96)
Pre-dialysis 0.38 <0.0001 0.78 (0.62, 0.95)
Cumulative Post-dialysis 0.53 <0.0001 0.74 (0.57, 0.92)
Intra-dialysis 0.51 0.0009 0.74 (0.58, 0.90)
† LVM/m2 = LVM indexed to patient's BSA, using the formula described by DuBois and DuBois19
†† LV hypertrophy was defined as an LVM/m2 >83 for males and LVM/m2 >67 for females20
Figure 2 ROC curves for different systolic BP measurement methods . The diagonal dotted line indicates a hypothetical test with no predictive 
value
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patients with a wide range of ESRD etiologies, including
diabetes and heart failure, both of which contribute to LV
hypertrophy. The autonomic and cardiovascular dysfunc-
tion in these disease processes could have confounded
the BP-LV hypertrophy correlation. Further studies are
necessary to delineate whether these co-morbidities
affect the BP-LV hypertrophy relationship.
Conclusion
In summary, we found that a single standardized BP mea-
surement has strong predictive power for LV hypertro-
phy, but is not significantly better than casual post- and
intra-dialysis BP measurements taken at a single point in
time or over several months. For ease of practice, a single
standardized measurement performs just as well as the
more resource intensive cumulative measurements.
Given the poor agreement with other methods, and rela-
tively poor predictive power of a single pre-dialysis mea-
surement in predicting LV hypertrophy, the results of this
study also suggest that the current practice guidelines,
which advocate the use of pre-dialysis measurements for
chronic hemodialysis patients, warrants further study.
This study does not however provide strong evidence to
disregard current guidelines.
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